Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Theralase Technologies Inc (TSV: TLT )

0.1600 UNCHANGED
Streaming Delayed Price Updated: 2:51 PM EDT, May 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.1600
Bid (Size) 0.1600 (1,045)
Ask (Size) 0.1650 (290)
Prev. Close 0.1600
Today's Range 0.1600 - 0.1600
52wk Range 0.1500 - 0.3100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Theralase(R) Expands Clinical Team
Via ACCESSWIRE
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
Via ACCESSWIRE

Performance

YTD
-13.51%
-13.51%
1 Month
-8.57%
-8.57%
3 Month
-23.81%
-23.81%
6 Month
-13.51%
-13.51%
1 Year
-41.82%
-41.82%

More News

Read More
Theralase(R) Granted Canadian Cancer Vaccine Patent
Via ACCESSWIRE
Theralase(R) Release's 4Q2023 Interim Financial Statements
Via ACCESSWIRE
Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
Via ACCESSWIRE
Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study
Via ACCESSWIRE
Theralase(R) Provides Update on Bladder Cancer Clinical Study
Via ACCESSWIRE
Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease
Via ACCESSWIRE
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Via ACCESSWIRE
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
Via ACCESSWIRE
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
Via ACCESSWIRE
Theralase(R) Files US Patent for Enhanced Immunotherapy
Via ACCESSWIRE
Theralase Release’s 3Q2023 Interim Financial Statements
Via ACCESSWIRE
Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement
Via ACCESSWIRE
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Via ACCESSWIRE
Theralase(R) Announces Brokered LIFE Financing
Via ACCESSWIRE
Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)
Via ACCESSWIRE
Theralase(R) Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer
Via ACCESSWIRE
Theralase(R) Grants Stock Options
Via ACCESSWIRE
Theralase(R) Closes Private Placement Equity Financing
Via ACCESSWIRE
Theralase Release’s 2Q2023 Interim Financial Statements
Via ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement Equity Financing
Via ACCESSWIRE
Theralase(R) Announces Appointment of New Independent Director
Via ACCESSWIRE
Theralase(R) Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements
Via ACCESSWIRE
Theralase(R) Releases 1Q2023 Interim Financial Statements
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.